0
     

Report Added
Report already added
Indian Pharma Sector Forecast 2026

Indian Pharma Sector Forecast 2026

The Indian pharma industry has always been a leading industrial sector in the country, with a paralleled dominance of both domestic and foreign pharma companies. As a result of the vast potential held by the industry, it was estimated to have generated revenue worth US$ 49 Billion in FY 2021. Growing population of middle-class, rapid shift towards urbanization, enhanced medical infrastructure, increase in health insurance and lifestyle-related disease are some of the major factors for the growth of the industry.

According to our new research report “Indian Pharma Sector Forecast 2026”, the rise in continuous investments by multinational companies and exports project a double-digit growth in near future. A large percentage of pharma products produced in India are exported, which has led the leading players to expand their reach into the Western nations. Due to the investments in R&D and the quest for more and more ANDA filings, the clinical trials market is growing at blistering pace. For comprehensive outlook of the industry, our in-depth and extensive research covers various segment ranging from the export and domestic market, bulk drugs & formulations to branded & generic drugs, etc.

The progress in the reach to medicines among Indians sets the baseline for the optimistic future outlook of the pharmaceutical market. The focus of the industry will shift towards capitalizing the potential of Tier-III and rural areas. Sectors such as biosimilars and CRAMS will continue pave way for the pharmaceutical market during the forecast period (FY 2022-2026).

The report offers a comprehensive statistical and analytical overview of the Indian pharmaceutical industry. It offers data on past, present, and future trends, with a focus on the pharmaceutical market's overall structure, makeup, and operation. The research goes into great detail about the opportunities and challenges that are predicted to occur both within and outside the pharmaceutical industry.

The research also looks at the pharmaceutical industry's regulatory framework and distribution structure. It has thoroughly investigated current market trends, developments, and competitive landscapes in order to help clients comprehend the market structure and its trajectory in the coming years. It also gives a quick rundown of the demographics and healthcare profile in order to assess the pharmaceutical market in terms of demand, spending, and potential future direction.
Table of Contents

1.Analyst View
2.Market Drivers
2.1Macroeconomic & Demographic Profile
2.2Product Patent Regime
2.3Medical Infrastructure
2.4Prevalence of Lifestyle-related Diseases
3.Indian Pharmaceutical Industry
3.1Industry Overview
3.2Domestic & Exports Market
3.3Future Outlook
4.Market Segmentation
4.1Patented & Generics
4.2Type of Drugs
4.2.1Bulk Drugs/APIs
4.2.2Formulations
4.3By Therapeutics
4.3.1Acute Segment
4.3.1.1Anti-Infectives
4.3.1.2Gastrointestinal
4.3.1.3Vitamins/Minerals/Nutrients
4.3.1.4Pain/Analgesics
4.3.1.5Dermatology
4.3.1.6Gynecology
4.3.1.7Respiratory
4.3.2Chronic Segment
4.3.2.1Cardiac
4.3.2.2Neuro/CNS
4.3.2.3Anti-Diabetic
5.Distribution Channel Analysis
6.Regulatory Overview
6.1Industry Regulations
6.2Government Initiatives
6.2.1Union Government
6.2.2State Government
7.Growth Accelerators
7.1Biosimilar
7.2CRAMS
7.3Bioinformatics
7.4Clinical Trials
7.5Pharma Packaging Industry
8.Competitive Landscape
8.1Market Structure
8.2Mergers & Acquisitions
8.3Key Players Analysis
8.3.1Aurobindo Pharma
8.3.2Cipla Limited
8.3.3Dr. Reddys Labs
8.3.4Sun Pharma
8.3.5Lupin Ltd.95


List of Figures:

Figure 2 1: FDI Equity Inflow (Billion US$), FY 2017 to FY 202210
Figure 2 2: FDI Equity Inflow in Pharmaceuticals (Billion US$), FY 2020 to FY 202211
Figure 3 1: Pharmaceutical Industry (Billion US$), FY 2016 to FY 202120
Figure 3 2: Breakup of Pharmaceutical Industry (%), FY 202121
Figure 3 3: Domestic Pharmaceutical Market (Billion US$), FY 2016 to FY 202122
Figure 3 4: Export of Pharmaceuticals (Billion US$), FY 2016 to FY 202123
Figure 3 5: Pharmaceutical Exports by Segment (%), FY 202124
Figure 3 6: Domestic Pharmaceutical Market (Billion US$), FY 2022 to FY 202626
Figure 3 7: Worldwide Total Prescription Drug Revenue at Risk from Patent Expiration (Billion US$), 2022-202627
Figure 4 1: Domestic Drug Formulations Market by Category (%), FY 202630
Figure 4 2: Bulk Drugs Export (Billion US$), FY 2016 to FY 202133
Figure 4 3: Domestic Drug Formulations Market (Billion US$), FY 2016 to FY 202134
Figure 4 4: Drug Formulations Export (Billion US$), FY 2016 to FY 202136
Figure 4 5: Domestic Pharmaceutical Market by Therapeutic Category (%), FY 202137
Figure 4 6: Anti-Infectives Market (Million US$), FY 2021 & FY 202638
Figure 4 7: Gastrointestinal Drugs Market (Million US$), FY 2021 & FY 202640
Figure 4 8: Vitamins/Minerals/Nutrients Market (Million US$), FY 2021 & FY 202641
Figure 4 9: Pain/Analgesics Market (Million US$), FY 2021 & FY 202643
Figure 4 10: Dermatology Market (Million US$), FY 2021 & FY 202644
Figure 4 11: Gynecology Market (Million US$), FY 2021 & FY 202645
Figure 4 12: Number of Asthma Patients (Million), 2020 & 203046
Figure 4 13: Respiratory Drugs Market (Million US$), FY 2021 & FY 202647
Figure 4 14: Cardiac Drugs Market (Million US$), FY 2021 & FY 202648
Figure 4 15: Neuro/CNS Drugs Market (Million US$), FY 2021 & FY 202649
Figure 4 16: Number of adults (20–79 years) with Diabetes (Million), 2021 & 204551
Figure 4 17: Anti-Diabetic Market (Million US$), FY 2021 & FY 202651
Figure 5 1: Pharmaceutical Distribution Channel53
Figure 7 1: Contract Manufacture and Research Services Market (Billion US$), 2018 to 202671
Figure 7 2: Number of Registered Clinical Trials (2011-2017)75
Figure 7 3: Number of Approved Clinical Trials (2013 & 2021)76
Figure 7 4: Clinical Trials by Phase (%)77
Figure 7 5: Clinical Trials by Condition (%)77
Figure 7 6: Clinical Trials Market (Billion US$), 2021-202678
Figure 7 8: Pharma Packaging Market (Million US$), 2021-202679
Figure 8 1: Share of Leading Companies in Pharmaceutical Market (FY 2021)81

List of Tables:

Table 2 1: Macroeconomic Overview (2017-2021)9
Table 2 2: Demographic Characteristics (2017-2021)12
Table 3 1: Top 10 Countries for Exports of Pharmaceuticals (FY 2021)25
Table 7 1: Leading Approved Biosimilars India67
Table 8 1: Key Acquisitions in Pharmaceutical Industry82
Table 8 2: Aurobindo Pharma - Key Financials (Billion INR), FY 2019 to FY 202186
Table 8 3: Cipla Limited - Key Financials (Billion INR), FY 2019 to FY 202189
Table 8 4: Dr. Reddys Labs - Key Financials (Billion INR), FY 2019 to FY 202191
Table 8 5: Sun Pharma - Key Financials (Billion INR), FY 2019 to FY 202193
Table 8 5: Lupin - Key Financials (Billion INR), FY 2019 to FY 202197

Report Title: Indian Pharma Sector Forecast 2026


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW